Inhibrx Biosciences Q3 2026 Results: Net Loss of $38.7M, Loss Widens
Inhibrx Biosciences reported a net loss of $108.8 million for the nine months ended September 30, 2026, compared to $107.2 million in the prior year. The company significantly increased its cash position to $199.5 million following $175.0 million in debt proceeds, while its accumulated deficit grew to $355.0 million.
- Key figure
- Net loss $38.7M